Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ter Arkh ; 82(7): 41-7, 2010.
Artigo em Russo | MEDLINE | ID: mdl-20853608

RESUMO

AIM: To analyze the efficiency of transplantation of the bone marrow from a HLA-compatible unrelated donor and continued immunosuppressive therapy (IST) in children with aplastic anemia (AA) unresponsive to 2 courses of IST. SUBJECTS AND METHODS: The study enrolled 14 children aged 2-16 years (median 9 years). A control group comprised 26 patients in whom IST was continued. The median interval between the diagnosis of AA and transplantation was 26 months (9-156 months). The conditioning regimen consisted of thoracoabdominal irradiation in a dose of 2 Gy, fludarabin (Flu) 100-150 mg/m2, cyclophosphamide (Cy) 100-200 mg/kg, antithymocyte globulin (ATG) in 11 patients and Flu, Cy, and ATG in 3. A graft-versus-host reaction was prevented with mycophenolate mefetil in all the patients, tacrolimus in 11, and cyclosporin A in 3. Donors were compatible for high-resolution typing of 10/10 and 9/10 alleles in 8 and 6 patients, respectively; the source of a transplant was bone marrow in 13 patients and granulocyte colony-stimulating factor-mobilized peripheral blood precursors in one case. RESULTS: Thirteen patients achieved primary engraftment after single transplantation; one patient did after repeat transplantation. Grades I to II graft-versus-host reaction (GVHR) developed in 9 patients; postengraftment life-threatening infections in 3, extensive chronic GVHR in 2, circumscribed GVHR in 7. All fourteen hemopoietic cell transplant recipients followed for a median 17.5 months (range 1-71 months) were survivors. CONCLUSION: The likelihood of good survival after unrelated transplantations in AA is much higher than that after continued IST: 100% versus 15 +/- 11%.


Assuntos
Anemia Aplástica/cirurgia , Soro Antilinfocitário/uso terapêutico , Transplante de Medula Óssea/métodos , Ciclosporina/uso terapêutico , Antígenos HLA , Imunossupressores/uso terapêutico , Doadores de Tecidos , Condicionamento Pré-Transplante/métodos , Adolescente , Anemia Aplástica/tratamento farmacológico , Anemia Aplástica/etiologia , Anemia Aplástica/imunologia , Anemia Aplástica/radioterapia , Soro Antilinfocitário/administração & dosagem , Criança , Pré-Escolar , Terapia Combinada , Ciclosporina/administração & dosagem , Intervalo Livre de Doença , Sobrevivência de Enxerto , Reação Enxerto-Hospedeiro/imunologia , Antígenos HLA/genética , Humanos , Imunossupressores/administração & dosagem , Falha de Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...